• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CTNNB1 Gene Record

  • Summary
  • Interactions
  • Claims
  • CTNNB1 1499 Druggable GenomeClinically ActionableDrug Resistance

    Alternate Names:

    1499
    CATENIN BETA 1
    CTNNB1
    CTNNB
    EVR7
    MRD19
    armadillo
    116806
    2514
    ENSG00000168036
    OTTHUMG00000131393
    PA27013
    P35222
    1290
    Beta-catenin
    T82795
    NEDSDV
    OK/SW-cl.35
    PRO2286
    Catenin beta-1

    Gene Info:

    Target Class Miscellaneous
    Target Subclass StructuralAndAdhesion
    Target Subclass beta-Catenin
    Gene Biotype PROTEIN_CODING
    (11 More Sources)

    Gene Categories: Category Details

    TRANSCRIPTION FACTOR COMPLEX
    DRUG RESISTANCE
    DRUGGABLE GENOME
    CLINICALLY ACTIONABLE
    TRANSCRIPTION FACTOR

    Publications:

    Arqués et al., 2016, Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer., Clin. Cancer Res.
    Butrym A et al., 2015, Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment., Leuk Res
    Henen MA et al., 2012, Toward rational fragment-based lead design without 3D structures., J Med Chem
    Lee MA et al., 2013, Anti-proliferative activity of hydnocarpin, a natural lignan, is associated with the suppression of Wnt/β-catenin signaling pathway in colon cancer cells., Bioorg Med Chem Lett
    Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
    Kasper et al., 2016, Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01)., Ann. Surg. Oncol.
    Gurney et al., 2012, Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors., Proc. Natl. Acad. Sci. U.S.A.
    Myers et al., 2016, Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study., Gynecol. Oncol.
    Peng et al., 2015, Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers., Cancer Cell
  • CHEMBL2172378   CTNNB1

    Interaction Score: 7.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22889313


    Sources:
    DTC

  • FLUORESCEIN SODIUM   CTNNB1

    Interaction Score: 7.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22889313


    Sources:
    DTC

  • EOSIN_Y   CTNNB1

    Interaction Score: 7.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22889313


    Sources:
    DTC

  • CHEMBL91638   CTNNB1

    Interaction Score: 3.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24018191


    Sources:
    DTC

  • TRICIRIBINE   CTNNB1

    Interaction Score: 1.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy NVP-TNKS656 + Triciribine
    Indication/Tumor Type colon cancer
    Response Type predicted – sensitive

    PMIDs:
    26224873


    Sources:
    JAX-CKB

  • VANTICTUMAB   CTNNB1

    Interaction Score: 1.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colon cancer
    Response Type predicted – sensitive
    Approval Status Preclinical - Pdx

    PMIDs:
    22753465


    Sources:
    JAX-CKB

  • LENALIDOMIDE   CTNNB1

    Interaction Score: 0.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26521987


    Sources:
    PharmGKB

  • TEMSIROLIMUS   CTNNB1

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type endometrial cancer
    Response Type predicted – sensitive
    Approval Status Phase II

    PMIDs:
    27016228


    Sources:
    JAX-CKB

  • CHEMBL410484   CTNNB1

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL533293   CTNNB1

    Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DITHIAZANINE IODIDE   CTNNB1

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • THALIDOMIDE   CTNNB1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26521987


    Sources:
    PharmGKB

  • TRAMETINIB   CTNNB1

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type liver cancer
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    26343583


    Sources:
    JAX-CKB

  • IMATINIB   CTNNB1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Clinical Study
    Response Type sensitive

    PMIDs:
    26861905


    Sources:
    JAX-CKB

  • CELECOXIB   CTNNB1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22336956


    Sources:
    PharmGKB

  • CYCLOPHOSPHAMIDE   CTNNB1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26521987


    Sources:
    PharmGKB

  • DEXAMETHASONE   CTNNB1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26521987


    Sources:
    PharmGKB

  • Ensembl: ENSG00000168036

    • Version: 101_38

    Alternate Names:
    CTNNB1 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TdgClinicalTrial: P35222

    • Version: January-2014

    Alternate Names:
    CTNNB1 Gene Symbol

    Gene Info:
    Target Class Miscellaneous
    Target Subclass StructuralAndAdhesion
    Target Subclass beta-Catenin

    Publications:

  • JAX-CKB: CTNNB1

    • Version: 27-September-2017

    Alternate Names:
    1499 CKB Entrez Id
    CTNNB1 CKB Gene Synonym
    armadillo CKB Gene Synonym

    Gene Info:

    Publications:
    Gurney et al., 2012, Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors., Proc. Natl. Acad. Sci. U.S.A.
    Delgado et al., 2014, Identification and characterization of a novel small-molecule inhibitor of β-catenin signaling., Am. J. Pathol.
    Tian et al., 2012, Structure-based discovery of a novel inhibitor targeting the β-catenin/Tcf4 interaction., Biochemistry

  • PharmGKB: CTNNB1

    • Version: 18-August-2020

    Alternate Names:
    PA27013 PharmGKB ID

    Gene Info:

    Publications:
    Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
    Butrym A et al., 2015, Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment., Leuk Res

  • CIViC: CTNNB1

    • Version: 14-September-2020

    Alternate Names:
    1499 Entrez Gene ID
    1290 CIViC Gene ID

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE

    Publications:
    Spranger et al., 2015, Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity., Nature

  • TTD: Beta-catenin

    • Version: 2020.06.01

    Alternate Names:
    CTNNB1 TTD Gene Abbreviation
    T82795 TTD Target ID

    Gene Info:

    Publications:
    Burnett JC et al., 2011, Current progress of siRNA/shRNA therapeutics in clinical trials., Biotechnol J

  • DTC: CTNNB1

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Henen MA et al., 2012, Toward rational fragment-based lead design without 3D structures., J Med Chem
    Lee MA et al., 2013, Anti-proliferative activity of hydnocarpin, a natural lignan, is associated with the suppression of Wnt/β-catenin signaling pathway in colon cancer cells., Bioorg Med Chem Lett

  • HingoraniCasas: ENSG00000168036

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000168036 Gene Symbol
    CTNNB1 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • GO: CTNNB1

    • Version: 01-February-2022

    Alternate Names:
    CTNNB GO Gene Synonym
    OK/SW-cl.35 GO Gene Synonym
    PRO2286 GO Gene Synonym

    Gene Info:

    Gene Categories:
    TRANSCRIPTION FACTOR COMPLEX

    Publications:

  • Tempus: CTNNB1

    • Version: 11-November-2018

    Alternate Names:
    CTNNB1 Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • Pharos: CTNNB1

    • Version: 01-February-2022

    Alternate Names:
    Catenin beta-1 Gene Name
    P35222 UniProt ID

    Gene Info:

    Gene Categories:
    TRANSCRIPTION FACTOR

    Publications:

  • MskImpact: CTNNB1

    • Version: May-2015

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • FoundationOneGenes: CTNNB1

    • Version: 03-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • CarisMolecularIntelligence: CTNNB1

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • Oncomine: CTNNB1

    • Version: v3

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21